

Ref: Invicta/BSE/BMO/Q1/2018-19

Date : 14.08.2018

To
The Deputy Manager
BSE Limited
P J Towers, Dalal Street,
Mumbai – 400 001

Dear Sir,

Sub: Outcome of Board Meeting held on 14th August, 2018.

Ref : Scrip Code : 523844 of Invicta Meditek Limited

We wish to inform you that the Board of Directors of the Company in its meeting held on today, i.e., Tuesday the 14th day of August, 2018 at the Registered Office, have transacted the following business:

1. Considered and Approved the Un-audited financial results of the Company for the Quarter ended 30th June, 2018 along with the Limited Review Report.


The meeting of Board of Directors of the Company commenced at 06:00 P.M and concluded at 07:45 P.M.

This is for your kind information and records.

Thanking you,

Yours faithfully,
For Invicta Meditek Limited

R.Sundararaghavan
Managing Director
(DIN: 01197824)



LIMITED REVIEW REPORT

To


The Board of Directors of
M/s. Invicta Meditek Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s. Invicta Meditek Limited** for the period ended 30th June 2018 which has been prepared in compliance with IND-AS. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


We draw attention to Note No. 2 regarding the non compliance with the provisions of section 185 of the Companies Act 2013 in respect of loan given to a director and outstanding as on 30.06.2018.

We also draw attention to the Note no. 3 of the Unaudited Financial Results. The company has not carried out any operations during the period covered by Review. In view of the above, there is material certainty that cast significant doubt about the entity's ability to continue as a going concern.




Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Chennai
Date : 14.08.2018



For Chandran & Raman
Chartered Accountants
FRN No. 00571S


S. Pattabiraman
Partner
M No. 14309

INVICTA MEDITEK LIMITED
Shop No.G-27, Phase 1, Ground Floor, Spencer Plaza, Anna Salai, Chennai - 600 002
Profit and loss statement for the quarter ended 30.06.2018

(Amount in Lakhs)

S.No	Particulars	Quarter ended		Year ended	
		June 30, 2018	March 31, 2018	June 30, 2017	March 31 2018
		(UnAudited)	(Audited)	(UnAudited)	Audited
I.	Revenue from operations	-	-	-	-
II.	Other income	-	17.34	-	17.34
III.	Total Revenue (I + II)	-	17.34	-	17.34
IV.	Expenses:				
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	-	18.93	-	18.93
	Employee benefits expense	0.75	0.75	0.71	2.96
	Finance costs	-	-	-	-
	Depreciation and amortization expense	-	-	-	-
	Other expenses	0.38	2.11	3.83	8.32
	Less: Expenses capitalized				
	Total expenses (IV)	1.13	21.79	4.54	30.21
V.	Profit before exceptional and extraordinary items and tax (III-IV)	-1.13	-4.45	-4.54	-12.87
VI.	Exceptional items			-	-
VII.	Profit before extraordinary items and tax (V + VI)	-1.13	-4.45	-4.54	-12.87
VIII.	Extraordinary Items			-	-
IX	Profit before tax (VII- VIII)	-1.13	-4.45	-4.54	-12.87
X	Tax expense:				
	(1) Current tax	-	-	-	-
	- Current Year (Net of Mat Credit)				
	- Previous year Tax				
	(2) Deferred tax	-	-	-	-
XI	Profit (Loss) for the period from continuing operations (IX-X)	-1.13	-4.45	-4.54	-12.87
XII	Profit/(loss) from discontinuing operations			-	-
XIII	Tax expense of discontinuing operations			-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XIII-XIV)			-	-
XV	Profit (Loss) for the period (XIII + XIV)	-1.13	-4.45	-4.54	-12.87
XVI	Other Comprehensive Income				
	a) Items that will not be reclassified to P&L a/c				
	1) Re-measurements of defined benefit plans				
XVII	Total comprehensive Income for the period (XV+XVI)				
XVIII	Paid up Equity Share Capital (Face value of Rs.10/- per share)	720.90	720.90	720.90	720.90
IX	Paid up Debt capital/ Outstanding Debt				
	Reserves excluding Revaluation Reserve				
XX	Debt redemption Reserve				
XXI	Earnings Per Equity Share before movement in Regulatory balances				
	(1) Basic	-0.02	-0.06	-0.06	-0.18
	(2) Diluted	-0.02	-0.06	-0.06	-0.18

For Invicta Meditek Ltd.,



R Sundararaghavan
Managing Director

K Chandraprakash
Director

Place : Chennai
Date : 14.08.2018

1. The Company has adopted Indian Accounting Standards (IND AS) as prescribed under Section 133 of Companies Act, 2013 with effect from 01st April 2017 and also Ind AS 115 - "Revenue from contracts with customers" from 01.04.2018. The financial results for the quarter ended 30th June 2018 are in compliance with IND AS and other accounting principles generally accepted in India. The results for the corresponding quarter ended 30th June 2017 are also in compliance with IND AS.
2. The Loan granted to a Director in the earlier accounting year and remaining outstanding as on 30.06.2018 is not in compliance with the provisions of section 185 of the companies act 2013. The amount of loan outstanding as on 30.06.2018 is Rs.70,54,171/-
3. The company has discontinued its operation since 24th of February 2009 and has sold its entire asset pursuant to sale agreement with TTK Healthcare Limited in the FY 2009-10. The Company has accumulated losses of Rs. 8,75,04,634/- which is more than 50% of its net worth.
4. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in the respective meeting held on 14.08.2018. The Statutory auditors of the Company have carried out Limited Review of the results of the Current quarter. The figures of the corresponding quarter drawn under IND AS are not subject to limited review. However, the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of affairs.
5. Figures of previous period have been regrouped / reclassified wherever necessary to conform to current period's classification
6. No investor complaints has been received and pending for the quarter under review.

Place: Chennai
Date : 14.08.2018

by Order of the Board
for INVICTA MEDITEK LIMITED



R Sundararaghavan
Managing Director / Compliance Officer